Home/Filings/4/0001415889-25-007431
4//SEC Filing

Aslan Fred 4

Accession 0001415889-25-007431

CIK 0001817241other

Filed

Mar 6, 7:00 PM ET

Accepted

Mar 7, 4:35 PM ET

Size

5.3 KB

Accession

0001415889-25-007431

Insider Transaction Report

Form 4
Period: 2025-03-05
Aslan Fred
DirectorPresident and CEO
Transactions
  • Award

    Common Stock

    2025-03-05+200,000416,665 total
Footnotes (2)
  • [F1]Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
  • [F2]Reflects reduction in the number of shares subject to the RSU granted on July 22, 2024 from 228,905 shares to 216,665 shares. The equity award was originally calculated based on the maximum offering size of the Company's initial public offering (IPO) and such award was subsequently adjusted following the partial exercise of the underwriters option to purchase additional shares in connection with the IPO.

Issuer

Artiva Biotherapeutics, Inc.

CIK 0001817241

Entity typeother

Related Parties

1
  • filerCIK 0001909362

Filing Metadata

Form type
4
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 4:35 PM ET
Size
5.3 KB